Xu jianmin
Quick facts
Marketed products
- chemotherapy of mFOLFOX6 or FOLFIRI · Oncology
mFOLFOX6 and FOLFIRI are combination chemotherapy regimens that inhibit DNA synthesis and cell division through multiple mechanisms targeting rapidly dividing cancer cells.
Phase 3 pipeline
- FUDR +oxaliplatin · Oncology
FUDR (floxuridine) and oxaliplatin work together as a chemotherapy combination to inhibit DNA synthesis and cross-link DNA, killing rapidly dividing cancer cells. - oxaliplatin+Leucovorin+5-FU · Oncology
Oxaliplatin works by interfering with DNA replication in cancer cells, while 5-FU is a thymidylate synthase inhibitor that disrupts DNA synthesis, and Leucovorin is a folate analog that helps stabilize 5-FU.
Competitive intelligence
For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors: